



## Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

May 1, 2018

NEW YORK--(BUSINESS WIRE)--May 1, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.

To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 2075643. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: [www.ophthotech.com](http://www.ophthotech.com). A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 2075643.

### About Ophthotech Corporation

Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. For more information, please visit [www.ophthotech.com](http://www.ophthotech.com).

### Forward-looking Statements

*Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.*

### OPHT-G

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180501005056/en/>

Source: Ophthotech Corporation

### Investors

Ophthotech Corporation  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and Corporate Communications  
[kathy.galante@ophthotech.com](mailto:kathy.galante@ophthotech.com)

or

### Media

SmithSolve LLC on behalf of Ophthotech Corporation  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)